An analysis of the administered therapy showed that 73% of the ICI-associated myocarditis cases occurred during monotherapy with anti-PD-1 drugs; in 17.6% of cases, a combination of anti-CTLA4 and anti-PD-1 therapy was used, while cases of myocarditis during monotherapy with anti-CTLA-4 (0.8%), anti-PD-L1 (7.8%), and combined anti-PD-1/anti-PD-L1 therapy (0.8%) were much less frequent. Here, PDCD1 is linked to myocarditis.